Metoprolol- Toprol XL

Phase 1Small molecule

Metoprolol- Toprol XL is one of 38 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

Acute Myocardial InfarctionPhase 1

Active, not recruiting

Competition

Competitive Landscape

216 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Adenocard

Astellas

Phase 3

2 2

Lovenox

Sanofi

Phase 3

2 3

Byetta

AstraZeneca

Phase 3

1 4

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 5

Jardiance

Boehringer Ingelheim

Phase 3

1 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 7

Glucophage

EMD Serono

Phase 3

1 8

Xarelto

WWim Janssens

Phase 3

1 9

Allegra

CChattem

Phase 3

1 10

Penthrane

PPurdue Pharma, Canada

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Myocardial Infarction1 trial

Metoprolol in Acute Myocardial Infarction. A PK/PD Study

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01523054·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metoprolol- Toprol XL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metoprolol- Toprol XL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metoprolol- Toprol XL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

Metoprolol- Toprol XL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News